These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30914707)

  • 21. Butyrylcholinesterase K variant and the APOE-epsilon 4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients.
    Vaisi-Raygani A; Rahimi Z; Tavilani H; Pourmotabbed T
    Mol Biol Rep; 2010 Apr; 37(4):2083-91. PubMed ID: 19685167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease.
    Kehoe PG; Williams H; Holmans P; Wilcock G; Cairns NJ; Neal J; Owen MJ
    J Med Genet; 1998 Dec; 35(12):1034-5. PubMed ID: 9863603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Butyrylcholinesterase K variant and cerebral amyloid angiopathy.
    Yamada M; Sodeyama N; Itoh Y; Suematsu N; Otomo E; Matsushita M; Mizusawa H
    Stroke; 1998 Dec; 29(12):2488-90. PubMed ID: 9836756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
    Darreh-Shori T; Siawesh M; Mousavi M; Andreasen N; Nordberg A
    J Alzheimers Dis; 2012; 28(2):443-58. PubMed ID: 22012848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase.
    Darreh-Shori T; Modiri N; Blennow K; Baza S; Kamil C; Ahmed H; Andreasen N; Nordberg A
    Neurobiol Aging; 2011 Jul; 32(7):1236-48. PubMed ID: 19713000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease.
    Raygani AV; Zahrai M; Soltanzadeh A; Doosti M; Javadi E; Pourmotabbed T
    Neurosci Lett; 2004 Nov; 371(2-3):142-6. PubMed ID: 15519745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women.
    Alvarez-Arcaya A; Combarros O; Llorca J; Sánchez-Guerra M; Berciano J; Fernández-Viadero C; Peña N
    Acta Neurol Scand; 2000 Dec; 102(6):350-3. PubMed ID: 11125748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease.
    Tilley L; Morgan K; Grainger J; Marsters P; Morgan L; Lowe J; Xuereb J; Wischik C; Harrington C; Kalsheker N
    Eur J Hum Genet; 1999 Sep; 7(6):659-63. PubMed ID: 10482954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer's disease in males carrying an apolipoprotein E epsilon4 allele.
    Haasl RJ; Ahmadi MR; Meethal SV; Gleason CE; Johnson SC; Asthana S; Bowen RL; Atwood CS
    BMC Med Genet; 2008 Apr; 9():37. PubMed ID: 18439297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of CD33 rs3865444:C˃A polymorphism with a reduced risk of late-onset Alzheimer's disease in Slovaks is limited to subjects carrying the APOE ε4 allele.
    Javor J; Ďurmanová V; Párnická Z; Minárik G; Králová M; Pečeňák J; Vašečková B; Režnáková V; Šutovský S; Gmitterová K; Hromádka T; Peterajová Ľ; Shawkatová I
    Int J Immunogenet; 2020 Oct; 47(5):397-405. PubMed ID: 32333488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease.
    Brindle N; Song Y; Rogaeva E; Premkumar S; Levesque G; Yu G; Ikeda M; Nishimura M; Paterson A; Sorbi S; Duara R; Farrer L; St George-Hyslop P
    Hum Mol Genet; 1998 May; 7(5):933-5. PubMed ID: 9536099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
    Patterson CE; Todd SA; Passmore AP
    Pharmacogenomics J; 2011 Dec; 11(6):444-50. PubMed ID: 20644562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No association between butyrylcholinesterase K-variant and Alzheimer disease in Chinese.
    Lee DW; Liu HC; Liu TY; Chi CW; Hong CJ
    Am J Med Genet; 2000 Apr; 96(2):167-9. PubMed ID: 10893490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk.
    Combarros O; Riancho JA; Infante J; Sañudo C; Llorca J; Zarrabeitia MT; Berciano J
    Dement Geriatr Cogn Disord; 2005; 20(2-3):153-7. PubMed ID: 16020944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
    Han HJ; Kwon JC; Kim JE; Kim SG; Park JM; Park KW; Park KC; Park KH; Moon SY; Seo SW; Choi SH; Cho SJ
    Eur Neurol; 2015; 73(1-2):23-8. PubMed ID: 25376930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Butyrylcholinesterase signal sequence self-aggregates and enhances amyloid fibril formation in vitro.
    Jasiecki J; Targońska M; Janaszak-Jasiecka A; Kalinowski L; Waleron K; Wasąg B
    Chem Biol Interact; 2023 Dec; 386():110783. PubMed ID: 37884182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer's disease in Koreans.
    Kim KW; Jhoo JH; Lee JH; Lee KU; Lee DY; Youn JC; Youn JY; Woo JI
    J Neural Transm (Vienna); 2001; 108(10):1159-66. PubMed ID: 11725818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
    Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
    Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Butyrycholinesterase K variant and Alzheimer's disease.
    Panegyres PK; Mamotte CD; Vasikaran SD; Wilton S; Fabian V; Kakulas BA
    J Neurol; 1999 May; 246(5):369-70. PubMed ID: 10399868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.
    Bizzarro A; Guglielmi V; Lomastro R; Valenza A; Lauria A; Marra C; Silveri MC; Tiziano FD; Brahe C; Masullo C
    J Neural Transm (Vienna); 2010 Mar; 117(3):377-83. PubMed ID: 20058037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.